CTOs on the Move

AgBiome

www.agbiome.com

 
AgBiome® partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS™ discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiary, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler®, is a revolutionary fungicide for disease control in a broad variety of crops.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.agbiome.com
  • 104 T. W. Alexander Drive Building 18
    Research Triangle Park, NC USA 27709
  • Phone: 984.234.1472

Executives

Name Title Contact Details
Rick Bartschi
 Chief Technology Officer Profile

Funding

AgBiome raised $34.5M on 08/20/2015
AgBiome raised $65M on 07/12/2018

Similar Companies

Celsis Inc

Celsis Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Datavant

Datavant connects healthcare data to eliminate the silos of healthcare information that hold back innovative medical research and improved patient care. We help data owners manage the privacy, security, compliance, and trust required to enable safe data sharing. Datavant`s vision is backed by Roivant Sciences, Softbank, and Founders Fund, and combines technical leadership and healthcare expertise. Datavant is located in the heart of San Francisco`s Financial District.

Celcuity

Celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform.

US Bio Solutions

US Bio Solutions is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.